IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 7h
IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • Saturday
IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • Friday
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • Thursday
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/19/24
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/17/24
Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 WeeksZacks Investment Research • 05/17/24
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex ProgramBusiness Wire • 05/17/24
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/16/24
After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)Zacks Investment Research • 05/16/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/15/24
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/24
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsBusiness Wire • 05/08/24
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceBusiness Wire • 05/02/24
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024Business Wire • 05/01/24
Marinus Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - MRNSAccesswire • 04/22/24
Investors who lost money on Marinus Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - MRNSAccesswire • 04/21/24
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Marinus Pharmaceuticals, Inc. (MRNS)Accesswire • 04/19/24
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire • 04/17/24
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure StudyZacks Investment Research • 04/16/24
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsBusiness Wire • 04/15/24
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire • 04/05/24
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant ReviewBusiness Wire • 03/27/24